• Phosbind Acrylamide: Advancing Phosphate-Binding Reagent Wor

  2026-05-27

  Phosbind Acrylamide enables rapid, antibody-free detection of protein phosphorylation states, streamlining SDS-PAGE workflows for signaling research. Its selective phosphate-binding at physiological pH makes it ideal for dissecting phosphorylation-dependent processes, as demonstrated in recent addiction neuroscience studies.

• Nicotinamide Riboside Chloride: Enhancing NAD+ in RGC Models

  2026-05-26

  Nicotinamide Riboside Chloride (NIAGEN) revolutionizes metabolic and neurodegenerative research by reliably boosting NAD+ and supporting advanced stem cell workflows. Its robust solubility profile and high purity make it the preferred choice for retinal ganglion cell and metabolic dysfunction studies, enabling reproducible results and translational breakthroughs.

• Nascent Cone Precursors Identified as the Cell-of-Origin in

  2026-05-26

  This study leverages RB1-deficient human retinal organoids and single-cell transcriptomics to pinpoint ATOH7+/RXRγ+ nascent cone precursors as the earliest cellular origin of human retinoblastoma. The findings refine our understanding of tumor initiation and highlight new avenues for targeted therapy development.

• Decitabine (5-Aza-2'-deoxycytidine): Epigenetic Mechanisms &

  2026-05-25

  Decitabine (5-Aza-2'-deoxycytidine) is a potent DNA methyltransferase 1 inhibitor widely used in hematopoietic malignancy research. It induces DNA hypomethylation and reactivates silenced tumor suppressor genes, with robust evidence supporting its use in both solid tumor and immunotherapy workflows.

• Nicotinamide Riboside Chloride: Precision in Neurodegenerati

  2026-05-25

  Nicotinamide Riboside Chloride (NIAGEN) empowers researchers to elevate NAD+ metabolism and reproducibility in metabolic dysfunction and neurodegenerative disease models. This article translates landmark retinal ganglion cell differentiation workflows into actionable protocols, troubleshooting strategies, and advanced applications for experimental success.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-05-24

  The DiscoveryProbe™ Metabolism-related Compound Library provides researchers with a rigorously validated set of 493 small molecules targeting metabolic enzymes and pathways, designed for in vitro and ex vivo metabolic studies. This library addresses the need for reproducible, high-throughput screening and pathway elucidation in metabolism research, but is not intended for diagnostic, clinical, or in vivo applications.

• SP2509: Lysine-Specific Demethylase 1 Antagonist for AML Res

  2026-05-23

  SP2509 is a selective lysine-specific demethylase 1 antagonist that enables robust apoptosis induction and differentiation in acute myeloid leukemia models. This guide delivers protocol enhancements, troubleshooting strategies, and cutting-edge workflow insights for maximizing SP2509’s impact in cancer epigenetics research.

• Primidone (SKU B2120): Reliable TRPM3 & RIPK1 Inhibition for

  2026-05-22

  This scenario-driven guide demonstrates how Primidone (SKU B2120) from APExBIO addresses critical workflow challenges in cell-based assays, neurodegenerative disease modeling, and translational research. Readers gain actionable, evidence-backed insights for TRPM3 and RIPK1 inhibition, protocol optimization, and product selection to ensure reproducibility and mechanistic clarity.

• Decitabine Primes CD8+ T Cells to Enhance Anti–PD-1 Efficacy

  2026-05-22

  The referenced JCI study demonstrates that low-dose Decitabine preconditioning promotes expansion and effector function of CD8+ progenitor exhausted T cells, thereby improving the antitumor activity of anti–PD-1 therapy in preclinical tumor models. These findings clarify an epigenetic mechanism that may help overcome immunotherapy resistance in cancer research.

• High-Throughput Surrogate BBB Model: Predicting CNS Drug Per

  2026-05-21

  The referenced study introduces a physiologically relevant, high-throughput blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, improving the prediction of CNS drug permeability. By integrating lysosomal trapping correction, the model more accurately reflects in vivo brain distribution, offering a robust tool for early-stage neuropharmacology research and CNS drug development.

• Rotenone and Mitochondrial Complex I: Strategic Pathways for

  2026-05-21

  This article explores how Rotenone, a benchmark mitochondrial Complex I inhibitor, empowers translational researchers to interrogate mitochondrial dysfunction, apoptosis, and autophagy. Integrating mechanistic insights from recent discoveries about TCAIM-mediated metabolic regulation, we provide actionable guidance on experimental design, highlight competitive research strategies, and offer a future-facing perspective on disease modeling and therapeutic innovation.

• Decitabine (5-Aza-2'-deoxycytidine): Protocols and Innovatio

  2026-05-20

  Decitabine (5-Aza-2'-deoxycytidine) is revolutionizing both hematopoietic malignancy and solid tumor epigenetic studies by enabling precise DNA demethylation and tumor suppressor gene reactivation. This article details actionable workflows, advanced experimental use-cases, and troubleshooting insights—empowering cancer epigenetics researchers to maximize data quality and biological impact with APExBIO’s trusted formulation.

• M344 HDAC Inhibitor Suppresses Neuroblastoma Growth In Vivo

  2026-05-20

  The referenced study demonstrates that the histone deacetylase inhibitor M344 robustly suppresses tumor growth and alters malignant phenotypes in neuroblastoma models. Its superior cytostatic, cytotoxic, and migration-inhibitory effects compared to established agents highlight M344’s promise for advancing pediatric cancer research and therapy.

• Belinostat (PXD101): Precision HDAC Inhibition in Cancer Res

  2026-05-19

  Belinostat (PXD101) is redefining epigenetic cancer research with nanomolar potency and highly reproducible HDAC inhibition. This article bridges bench workflows with advanced troubleshooting to maximize performance in bladder and prostate cancer models.

• Nirmatrelvir (PF-07321332) Advances SARS-CoV-2 Inhibition Re

  2026-05-19

  Nirmatrelvir (PF-07321332) empowers researchers to dissect and disrupt SARS-CoV-2 replication by selectively targeting 3CL protease. This guide delivers optimized workflows, troubleshooting insights, and context from in silico discovery to wet-lab protocol design, highlighting APExBIO’s commitment to rigor and reproducibility.

15771 records 2/1052 page Previous Next 12345 下5页 Last page